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Abstract
Background: The incidence of acute complications and mortality associated with COVID-19 remains poorly
characterized. The aims of this systematic review and meta-analysis were to summarize the evidence on clinically
relevant outcomes in hospitalized patients with COVID-19.
Methods: MEDLINE, EMBASE, PubMed, and medRxiv were searched up to April 20, 2020, for studies including
hospitalized symptomatic adult patients with laboratory-confirmed COVID-19. The primary outcomes were all-cause
mortality and acute respiratory distress syndrome (ARDS). The secondary outcomes included acute cardiac or kidney
injury, shock, coagulopathy, and venous thromboembolism. The main analysis was based on data from peer-reviewed
studies. Summary estimates and the corresponding 95% prediction intervals (PIs) were obtained through meta-analyses.
Results: A total of 44 peer-reviewed studies with 14,866 COVID-19 patients were included. In general, risk of bias was
high. All-cause mortality was 10% overall (95% PI, 2 to 39%; 1687/14203 patients; 43 studies), 34% in patients admitted to
intensive care units (95% PI, 8 to 76%; 659/2368 patients; 10 studies), 83% in patients requiring invasive ventilation (95% PI,
1 to 100%; 180/220 patients; 6 studies), and 75% in patients who developed ARDS (95% PI, 35 to 94%; 339/455 patients;
11 studies). On average, ARDS occurred in 14% of patients (95% PI, 2 to 59%; 999/6322 patients; 23 studies), acute cardiac
injury in 15% (95% PI, 5 to 38%; 452/2389 patients; 10 studies), venous thromboembolism in 15% (95% PI, 0 to 100%;
patients; 3 studies), acute kidney injury in 6% (95% PI, 1 to 41%; 318/4682 patients; 15 studies), coagulopathy in 6% (95%
PI, 1 to 39%; 223/3370 patients; 9 studies), and shock in 3% (95% PI, 0 to 61%; 203/4309 patients; 13 studies).
Conclusions: Mortality was very high in critically ill patients based on very low-quality evidence due to striking
heterogeneity and risk of bias. The incidence of clinically relevant outcomes was substantial, although reported by only
one third of the studies suggesting considerable underreporting.
Trial registration: PROSPERO registration ID for this study is CRD42020177243 (https://www.crd.york.ac.uk/prospero/
display_record.php?RecordID=177243).
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Background
Clinical manifestations of Coronavirus disease 2019
(COVID-19) range from mild cases to severe pneumonia,
which may be complicated by an exaggerated systemic in-
flammatory response leading to acute respiratory distress
syndrome (ARDS), multiple organ failure, and death [1–3].
The largest report on COVID-19 from the Chinese Center
for Disease Control and Prevention showed that among 44,
672 confirmed cases, 80.9% were mild, 13.9% severe, and
4.7% critical. The overall case-fatality rate was 2.3% with
values as high as 49% in critical patients with respiratory
failure, septic shock, or multiple organ failure [4].
Since the start of the outbreak, observational studies
have extensively described the most prevalent clinical,
laboratory, and radiological presentations of COVID-19.
However, the clinical course of patients with COVID-19
remains poorly characterized, with heterogeneous and
discordant incidence of in-hospital complications and
mortality [5–7].
The aims of this systematic review and meta-analysis
were to evaluate current evidence on clinically relevant
outcomes in hospitalized symptomatic adult patients
with COVID-19 and identify factors which may predict
worse prognosis.
Methods
This study-level systematic review and meta-analysis was
performed following the Preferred Reporting Items for
Systematic reviews and Meta-analysis (PRISMA) guide-
lines [8].
The PROSPERO registration ID is CRD42020177243.
Databases search and study selection
MEDLINE, EMBASE (Ovid-SP), and PubMed were
searched from inception up to April 20, 2020, for obser-
vational studies and randomized controlled trials (RCTs)
in English language which included symptomatic adult
patients with COVID-19. This search was complemen-
ted with the screening of medRxiv, a free online archive
for complete but unpublished manuscripts (preprints) in
the health sciences (https://www.medrxiv.org/content/
about-medrxiv), until April 20, 2020. The preprints
available in medRxiv represent preliminary reports of
studies that have not been peer-reviewed yet; thus, they
may help to provide a comprehensive picture of the evi-
dence that may be published in future, but they should
not be relied on to guide clinical practice. The complete
search strategy is given in Additional file 1: Tables S1
and S2.
Two authors independently reviewed titles and abstracts
identified from the search to select studies which met the
following inclusion criteria: (i) observational study or RCT
enrolling ≥ 50 symptomatic outpatients or hospitalized pa-
tients, (ii) laboratory-confirmed COVID-19 defined by a
positive result on a reverse-transcriptase-polymerase-
chain-reaction assay of a nasopharyngeal and oropharyn-
geal swabs or a sputum specimen, and (iii) at least one of
the primary outcomes reported by the study. Case reports
and case series with less than 50 patients were excluded as
they may observe no events due to the small size. Full-text
screening was done independently by the same authors,
and any disagreement was resolved through discussion or
involving a third review author.
Data extraction and quality assessment
Two review authors independently extracted data from
the included studies. Any disagreement was resolved by
consensus between the two review authors or by involving
a third review author. The following data were extracted:
study characteristics (e.g., study design, health-care set-
ting), patients’ characteristics (e.g., age, sex), presence of
comorbidities (e.g., respiratory system disease, chronic
kidney disease, cardiovascular disease, diabetes, hyperten-
sion, malignancy), severity of COVID-19 disease at study
entry, treatment (e.g., antivirals, antibiotic therapy, inva-
sive ventilation and non-invasive oxygen support), and
clinical outcomes. We extracted the number of patients
with severe COVID-19 at study entry and recorded for
each study whether internationally accepted criteria or au-
thors’ own definitions were used [9–11].
The methodological quality was evaluated using the
methodological index for non-randomized studies (MI-
NORS) tool for observational studies and the Cochrane
tool for RCTs [12, 13]. The MINORS tool evaluates
eight study quality items and classifies them as adequate,
inadequate, or unclear [12]. The MINORS’ item on
blinded evaluation was deemed adequate for ARDS if an
external independent adjudication committee was in-
volved. The item related to the endpoint definition was
considered adequate if unambiguous criteria were used
to define the review outcomes. Follow-up duration was
considered adequate if all included patients were
followed up until hospital discharge or death.
Study outcomes
The primary outcomes were all-cause mortality and
ARDS. The secondary outcomes included shock, acute
kidney injury, acute cardiac injury, coagulopathy, venous
thromboembolism, and major bleeding events.
It was anticipated that outcome definitions varied
across included studies. This aspect was considered in
the evaluation of the study quality item regarding the ap-
propriateness of the criteria used to define the primary
outcomes. Standard criteria to diagnose the outcomes of
interest included the following: ARDS diagnosed accord-
ing to the Berlin definition [14]; shock defined as persist-
ing hypotension despite volume resuscitation, requiring
vasopressors to maintain mean arterial pressure ≥ 65
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mmHg and serum lactate level > 2 mmol/L [15]; acute
kidney injury diagnosed as an increase in serum creatin-
ine by ≥ 0.3 mg/dl within 48 h, ≥ 1.5 times from baseline
within 7 days, or urine volume < 0.5 ml/kg/h for 6 h [16];
acute myocardial injury diagnosed when there was a rise
and/or fall of cardiac troponin values with at least one
value above the 99th percentile of the upper reference
limit [17]; coagulopathy including the development of
disseminated intravascular coagulopathy defined accord-
ing to the International Society of Thrombosis and
Hemostasis [18], or abnormal values of specific coagula-
tion markers [19]; venous thromboembolism including
fatal or non-fatal pulmonary embolism and deep vein
thrombosis; and major bleeding defined according to the
criteria of the International Society of Thrombosis and
Hemostasis [20].
Statistical analysis
The main analysis was based on data extracted from
peer-reviewed studies that were retrieved from MED-
LINE, EMBASE, and PubMed databases. The analyses
performed on not peer-reviewed studies retrieved from
medRxiv were considered exploratory.
For descriptive purposes, we used the mean and stand-
ard deviation for continuous variables or the median and
range, where appropriate. Categorical variables were de-
scribed as counts and percentages. Summary estimates
and the corresponding 95% prediction intervals (PIs)
and 95% confidence intervals (CIs) were obtained
through meta-analyses. PIs show the extent of between-
study variation and predict the possible effect in a future
study that is comparable to those included in the meta-
analysis. Single proportions were logit transformed to
maintain symmetry in the random effects meta-analysis.
Confidence intervals for individual studies were esti-
mated with the Wilson score. Heterogeneity across the
included studies was evaluated by visual inspection of
forest plots, as estimates of I-squared are uninformative
in meta-analyses of single proportions. Stratified
random-effects meta-analyses were planned to evaluate
the impact on mortality of COVID-19 severity at study
entry (i.e., severe vs non-severe), older age (< 60 vs ≥ 60
years), presence of comorbidities, concomitant arterial
hypertension, admission to intensive care unit (ICU),
and requirement for invasive ventilation, if at least 10
studies contributed to the analyses. Stratified analyses
were planned only for peer-reviewed studies. The inci-
dence of all-cause mortality in patients developing ARDS
was also evaluated in stratified analysis. Severe cases of
COVID-19 develop complications like ARDS, shock,
acute kidney injury, or cardiac injury more often during
the first 2 weeks of hospitalization [9]. Thus, an add-
itional stratified analysis was planned to explore the ef-
fects of follow-up duration on the primary outcomes
comparing adequate follow-up duration versus inad-
equate follow-up duration [21].
Statistical analyses were performed using R studio ver-
sion 1.2.5001, “meta” and “forestplot” packages [22].
Results
A total of 4540 records were identified from the search of
MEDLINE, EMBASE, and PubMed databases, and 1559
additional records were found in the medRxiv archive
(Additional file 1: Fig. S1). After removing 1642 duplicates,
4354 records were excluded based on title and abstract
screening. Of the remaining 103 records, 24 were ex-
cluded by full-text evaluation. Finally, a total of 44 peer-
reviewed studies (one RCT and 43 observational studies)
including 14,866 patients with laboratory-confirmed
COVID-19 were considered in the primary analysis [1,
23–65], and 35 not peer-reviewed studies (one RCT and
34 observational studies) including 11,283 patients were
evaluated in the secondary analysis (Additional file 1). The
inter-reviewer agreement was excellent with a kappa stat-
istic of 0.92.
Characteristics of included studies
The main characteristics of peer-reviewed studies are re-
ported in Additional file 1: Table S3. Forty-one studies
were conducted in China or other Asian countries, 2 in
Western Europe, and 1 involved centers from the USA,
Canada, Europe, and Japan. Twenty-eight studies
(63.6%) were single centre and 16 (36.4%) multicentre.
The size of the study population ranged from 52 to 1591
patients. Forty-three studies (97.7%) enrolled only hospi-
talized patients, while one study considered both outpa-
tients and inpatients. Median hospital stay was 15 days
(range 8 to 29; 12 studies). All studies reported at least
one of the review primary outcomes, and 15 (34.1%)
provided data on one or more secondary outcomes.
The risk of bias of the peer-reviewed RCT was high
for blinding of participants and personnel, unclear for
blinding of outcome assessors, and low for all other do-
mains. The methodological quality of the 43 observa-
tional studies, one ambispective and 42 retrospective
cohorts, is summarized in Additional file 1: Fig. S2 and
Table S4. Sixteen studies (37%) reported consecutive in-
clusion of patients. Follow-up duration was adequate in
seven studies and reported to be at least 2 weeks in thir-
teen studies. The main characteristics of not peer-
reviewed studies are shown in Additional file 1: Tables
S5 and S6.
Patient characteristics
The main patient characteristics reported in peer-
reviewed studies are given in Additional file 1: Table S7.
The mean age ranged between 38 and 69 years, and
8370 (56.4%) patients were males. The most common
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symptoms on admission were fever (7853/9822 patients
[79.9%]; 32 studies), cough (5965/9487 patients [62.9%];
30 studies), and dyspnea (2067/8810 patients [23.5%]; 25
studies). The most common comorbidities were hyper-
tension (2409/10310 patients [23.3%]; 29 studies), dia-
betes (1116/10435 patients [10.7%]; 31 studies),
cardiovascular disease (1018/10782 patients [9.4%]; 32
studies), and cancer (397/11019 patients [3.6%]; 29 stud-
ies). Pre-existent respiratory system disease was reported
in 2.8% of patients (312/11033 patients; 30 studies). Co-
infection was diagnosed in 14.0% of patients (255/1815
patients; 10 studies).
Twenty-nine studies (65.9%) reported the severity of
COVID-19 at study entry according to the criteria of
American Thoracic Society (3 studies), the National
Health Commission of the People’s Republic of China
(10 studies), the World Health Organization criteria (9
studies), or other classifications (7 studies). As many as
41.3% (5175/12530) of patients were considered to have
severe COVID-19 at study entry.
Most patients were managed in general wards, and
34.6% (2659/7687; 18 studies) were admitted to ICU. Sup-
plemental oxygen was administered to 36.3% of patients
(1959/5392; 18 studies), non-invasive ventilation to 8.7%
(589/6797; 20 studies), and invasive-mechanical ventila-
tion to 18.5% (1644/8901; 21 studies; see Additional file 1:
Table S8), whereas 0.9% of the patients required extracor-
poreal membrane oxygenation (39/4412; 16 studies). Con-
tinuous renal replacement therapy was used in 1.9% of
patients (86/4601; 14 studies).
The main characteristics of patients included in not
peer-reviewed studies are reported in Additional file 1:
Table S9. Twenty-four not peer-reviewed studies (68.6%)
reported the severity of COVID-19 according to the cri-
teria of American Thoracic Society (2 studies), the Na-
tional Health Commission of the People’s Republic of
China (4 studies), the World Health Organization criteria
(4 studies), or other classifications (14 studies). As many
as 31.8% (1902/5975) of patients of not peer-reviewed
studies were considered to have severe COVID-19 at
study entry. The type of treatment provided in not peer-
reviewed studies is shown in Additional file 1: Table S10.
Clinical outcomes
Figure 1 shows all-cause mortality in peer-reviewed
studies from Asian and Western countries, sorted by se-
verity of COVID-19 at study entry and the proportion of
patients admitted to ICU. The summary estimate for all-
cause mortality was 10% with substantial between-study
heterogeneity and large 95% PI (95% PI, 2 to 39%; 1687/
14203 patients; 43 studies) suggesting high uncertainty.
All-cause mortality was 34% in patients admitted to ICU
(95% PI, 8 to 76%; 659/2368 patients; 10 studies), 83% in
patients requiring invasive ventilation (95% PI, 1 to
100%; 180/220 patients; 6 studies), and 75% in patients
who developed ARDS (95% PI, 35 to 94%; 339/455 pa-
tients; 11 studies) with very high between-study hetero-
geneity (Figure 2). All-cause mortality in patients with
advanced age, one or more comorbidities, concomitant
arterial hypertension, and severe COVID-19 at study
entry and in studies with adequate follow-up is shown in
Additional file 1: Fig. S3.
Figure 3 shows ARDS outcome data in peer-reviewed
studies from Asian and Western countries sorted for se-
verity of COVID-19 at study entry and the proportion of
patients admitted to the ICU. On average, ARDS oc-
curred in 14% of patients with significant between-study
heterogeneity (95% PI, 2 to 59%; 999/6322 patients; 23
studies). Studies with follow-up until patient discharge
or death reported significantly higher ARDS risks com-
pared to studies with inadequate follow-up duration
(28% vs 11%; p = 0.002; Additional file 1: Fig. S4).
Figures 4 and 5 and Additional file 1: Table S11 show
outcome data for the secondary outcomes. In peer-
reviewed studies, the average summary estimates were
15% for acute cardiac injury (95% PI, 5 to 38%; 452/2389
patients; 10 studies), 15% for venous thromboembolism
(95% PI, 0 to 100%; patients; 3 studies), 6% for acute kid-
ney injury (95% PI, 1 to 41%; 318/4682 patients; 15 stud-
ies), 6% for coagulopathy (95% PI, 1 to 39%; 223/3370
patients; 9 studies), and 3% for shock (95% PI, 0 to 61%;
203/4309 patients; 13 studies). Major bleeding events
were reported in one study (2/199 patients; 1.0%).
The incidence of the primary and secondary outcomes
in not peer-reviewed studies was consistent with that of
the primary analysis (Additional file 1: Table S12 and
Figs. S5 to S10). As observed in peer-reviewed studies,
all summary estimates for primary and secondary out-
comes presented significant between-study heterogeneity
and wide prediction intervals.
Discussion
In this meta-analysis including 14,866 symptomatic adult
patients with COVID-19, all-cause mortality was 10%.
The incidence seemed three to eightfold higher in pa-
tients admitted to ICU, requiring invasive ventilation,
and those who developed ARDS based on very low qual-
ity evidence due to heterogeneity and risk of bias.
On average, mortality of COVID-19 patients admitted
to ICU was 34%, consistent with the results of a recent
large study of ICU patients with infection of the respira-
tory tract or other sites [66]. In ICU patients as well as
in those requiring invasive ventilation or developing
ARDS, prediction intervals were wide indicating very
low confidence in the summary estimates. Overall, these
findings suggest that different case mix with different
prognosis were included in the studies. Potential explan-
ation for heterogeneity include differences in age and
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Fig. 1 All-cause mortality in patients with COVID-19. All-cause mortality in peer-reviewed studies from Asian and Western countries, sorted by
severity of COVID-19 at study entry and the proportion of patients admitted to ICU. The vertical line indicates the summary estimate. Gray
squares indicate individual study estimates of the proportion of all-cause mortality, whereas the gray horizontal lines indicate 95% confidence
intervals of the individual studies. The diamond indicates the summary estimate with 95% confidence intervals. The horizontal black line refers to
the prediction intervals which are displayed numerically under the 95% confidence intervals. CI, confidence intervals; COVID-19, Coronavirus
disease 2019; ES, estimates; ICU, intensive care unit; PI, prediction intervals; USA, United States of America
Fig. 2 All-cause mortality in patients admitted to ICU, requiring invasive ventilation, and developing ARDS. The vertical line indicates the
summary estimate for all-cause mortality in total population. Gray squares indicate individual study estimates of the proportion of all-cause
mortality, whereas the gray horizontal lines indicate 95% confidence intervals of the individual studies. The diamonds indicate the summary
estimates with 95% confidence intervals. The horizontal black lines refer to the prediction intervals which are displayed numerically under the
95% confidence intervals. ARDS, acute respiratory distress syndrome; CI, confidence intervals; COVID-19, Coronavirus disease 2019; ES, estimates;
ICU, intensive care unit; PI, prediction intervals
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comorbidities between study populations, definition of
COVID-19-related deaths, and susceptibility or response
to COVID-19 [6, 67, 68]. Another potential explanation
for the heterogeneous risks of mortality and ARDS may
be related to the insufficient length of follow-up. The pro-
portion of patients who were still hospitalized at the end
of the study period was as high as 31.9% (Additional file 1:
Tables S11). The clinical outcomes of these patients re-
main unknown, which may have underestimated the ac-
tual incidence of complications which typically tend to
occur during the late hyperinflammatory phase of the dis-
ease. Only 7 studies followed patients until death or dis-
charge, and 13 studies had a follow-up of at least 14 days,
which may be regarded as a minimum follow-up duration
to observe clinically relevant outcomes [21]. Stratified ana-
lysis suggested that mortality and ARDS were significantly
higher in studies with adequate (20% and 28%) compared
to those with inadequate follow-up duration (9% and 11%,
respectively).
With regard to the secondary outcomes of this meta-
analysis, acute cardiac injury and venous thromboembol-
ism seemed to represent the most frequent complications
during hospitalization, followed by acute kidney injury, co-
agulopathy, and shock. As observed for the primary out-
comes, the uncertainty around all these estimates was
large. Importantly, information on secondary outcomes
was provided by only one third of the studies, suggesting
significant underreporting. In addition, it is unclear if
Fig. 3 ARDS in patients with COVID-19. ARDS in peer-reviewed studies from Asian and Western countries, sorted by severity of COVID-19 at study
entry and the proportion of patients admitted to ICU. The vertical line indicates the summary estimate. Gray squares indicate individual study
estimates of the proportion of ARDS, whereas the gray horizontal lines indicate 95% confidence intervals of the individual studies. The diamond
indicates the summary estimate with its 95% confidence intervals. The horizontal black line refers to the prediction intervals which are displayed
numerically under the 95% confidence intervals. ARDS, acute respiratory distress syndrome; CI, confidence intervals; COVID-19, Coronavirus disease
2019; ES, estimates; ICU, intensive care unit; PI, prediction intervals; USA, United States of America
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these outcomes were systematically evaluated in all pa-
tients, and we cannot exclude that our summary estimates
may represent an underestimation of actual incidence.
Nonetheless, our findings suggest that these acute compli-
cations are not infrequent and may have a relevant impact
on patient prognosis and burden for health care systems.
A better understanding of the risk and prompt recognition
of these complications could help to improve policies for
diagnosis and prevention, resource allocation, and help
the design of future interventional studies.
The current review has some limitations which need
to be discussed. Most studies were conducted in China
or other Asian countries which contributed to 88.1% of
all patients. The different accessibility and quality of
health care settings and resources within each country
and between countries may influence the representa-
tion of clinical outcomes and limit interpretation of
some of the findings. Most studies were retrospective,
and it was often unclear whether patients were enrolled
consecutively. The need to provide objective findings
Fig. 4 Acute cardiac and kidney injury in patients with COVID-19. Gray squares indicate individual study estimates of the proportion of the
outcomes, whereas the gray horizontal lines indicate 95% confidence intervals of the individual studies. The diamonds indicate the summary
estimates with 95% confidence intervals. The horizontal black lines refer to the prediction intervals which are displayed numerically under the
95% confidence intervals. CI, confidence intervals; COVID-19, Coronavirus disease 2019; ES, estimates; PI, prediction intervals
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and the urgent timeline of the disease may have af-
fected the quality of data recording and reporting. The
study-level analysis and poor reporting limited the
possibility to evaluate the effects of specific patient
characteristics, type of medical and supportive treat-
ment (e.g., requirement for kidney replacement ther-
apy) on clinical outcomes. All outcomes were
provided as crude proportions rather than time-to-
event rates (e.g., events per 100 patient days), which
incorporate a measure of the at-risk period, thereby
giving a more standardized and less biased summary
estimate. Finally, in light of the large between-study
heterogeneity observed, pooling of the individual
study estimates is debatable. For this reason, we fo-
cused on the prediction interval rather than the confi-
dence interval when describing results.
Fig. 5 Coagulopathy, shock, and venous thromboembolism in patients with COVID-19. Gray squares indicate individual study estimates of the
proportion of the outcomes, whereas the gray horizontal lines indicate 95% confidence intervals of the individual studies. The diamonds indicate
the summary estimates with 95% confidence intervals. The horizontal black lines refer to the prediction intervals which are displayed numerically
under the 95% confidence intervals. CI, confidence intervals; COVID-19, Coronavirus disease 2019; ES, estimates; PI, prediction intervals; VTE,
venous thromboembolism
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Conclusions
This systematic review and meta-analysis summarized
the current evidence on the incidence of mortality and
acute complications in hospitalized patients with
COVID-19. Mortality was very high in critically ill pa-
tients, based on very low-quality evidence with striking
heterogeneity. Health care professionals caring for
COVID-19 patients need to be aware of this variability
for medical decision making and communication.
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